Unnamed: 0,title,date,stock,sentiment
1174868.0,71 Biggest Movers From Yesterday,2020-06-02 04:39:00-04:00,SPRO,neutral
1174869.0,48 Stocks Moving In Monday's Mid-Day Session,2020-06-01 12:34:00-04:00,SPRO,neutral
1174870.0,"HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Raises Price Target to $28",2020-05-11 07:44:00-04:00,SPRO,neutral
1174871.0,"The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda",2020-05-08 07:59:00-04:00,SPRO,neutral
1174872.0,Spero Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem for the Treatment of Complicated Urinary Tract Infection,2020-05-05 16:15:00-04:00,SPRO,neutral
1174873.0,82 Biggest Movers From Yesterday,2020-04-29 04:30:00-04:00,SPRO,neutral
1174874.0,56 Stocks Moving In Tuesday's Mid-Day Session,2020-04-28 12:27:00-04:00,SPRO,neutral
1174875.0,96 Biggest Movers From Yesterday,2020-04-28 04:22:00-04:00,SPRO,neutral
1174876.0,72 Stocks Moving In Monday's Mid-Day Session,2020-04-27 12:34:00-04:00,SPRO,neutral
1174877.0,52 Biggest Movers From Yesterday,2020-04-22 04:36:00-04:00,SPRO,neutral
1174878.0,44 Stocks Moving In Tuesday's Mid-Day Session,2020-04-21 12:31:00-04:00,SPRO,neutral
1174879.0,130 Biggest Movers From Yesterday,2020-03-18 06:06:00-04:00,SPRO,neutral
1174880.0,"Stifel Maintains Buy on Spero Therapeutics, Lowers Price Target to $21",2020-03-17 10:10:00-04:00,SPRO,negative
1174881.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,SPRO,neutral
1174882.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,SPRO,negative
1174883.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,SPRO,negative
1174884.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,SPRO,negative
1174885.0,Spero Therapeutics Reports Receives FDA Orphan Drug Designation For SPR720 For Treatment Of Nontuberculous Mycobaterial Infection,2020-03-11 08:32:00-04:00,SPRO,neutral
1174886.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,SPRO,negative
1174887.0,Spero Therapeutics Reports Exercise Of $15.9M Option By BARDA For Tebipenem HBr Development,2020-02-05 08:11:00-05:00,SPRO,neutral
1174888.0,Spero Therapeutics To Raise $30M Via Rights Offering Of Convertible Shares,2020-01-30 08:09:00-05:00,SPRO,positive
1174889.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,SPRO,neutral
1174890.0,Spero Reports Preliminary Findings From Phase 1 Clinical Trial Of SPR206 Suggesting It Is Well-Tolerated At Doses Within Therapeutic Range For Target And Plans To Advance Program With Alliance Partners Everest Medicines And The Department Of Defense,2020-01-13 08:07:00-05:00,SPRO,positive
1174891.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,SPRO,neutral
1174892.0,Spero Reports Preliminary Findings From Phase 1 Clinical Trial Of SPR720; Says First Indication Of Human Safety And PK Profiles Supports Advancement Of Program To Phase 2a PRoof-Of-Concept Trial,2019-12-04 16:04:00-05:00,SPRO,positive
1174893.0,63 Biggest Movers From Yesterday,2019-11-21 04:49:00-05:00,SPRO,neutral
1174894.0,"H.C. Wainwright Maintains Buy on Spero Therapeutics, Raises Price Target to $35",2019-11-05 07:51:00-05:00,SPRO,neutral
1174895.0,"Spero Therapeutics Q3 EPS $(0.95) Misses $(0.85) Estimate, Sales $4.643M Beat $2.45M Estimate",2019-11-04 16:35:00-05:00,SPRO,negative
1174896.0,Spero Therapeutics Shares Up ~4-5% Over Last 15 Mins As Hearing Janney Raised Price Target On Stock To New Street High Of $31; BZ NOTE: Represents Potential Upside Of 187%,2019-10-03 11:25:00-04:00,SPRO,positive
1174897.0,Spero Therapeutics Highlights Recommendation To Continue Phase 3 Trial Of SPR994 As Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial,2019-10-03 08:09:00-04:00,SPRO,neutral
1174898.0,"Benzinga's Top Upgrades, Downgrades For September 9, 2019",2019-09-09 09:59:00-04:00,SPRO,positive
1174899.0,Janney Capital Initiates Coverage On Spero Therapeutics with Buy Rating,2019-09-09 06:45:00-04:00,SPRO,neutral
1174900.0,Spero Therapeutics 8-K Shows CFO Joel Sendek Resigned; Co. Has Commenced Search For Replacement,2019-09-06 08:49:00-04:00,SPRO,negative
1174901.0,"H.C. Wainwright Assumes Spero Therapeutics at Buy, Announces $28 Price Target",2019-09-04 07:20:00-04:00,SPRO,neutral
1174902.0,"Spero Therapeutics Q2 EPS $(0.74) Misses $(0.65) Estimate, Sales $2.156M Miss $5.05M Estimate",2019-08-08 17:03:00-04:00,SPRO,negative
1174903.0,Spero Therapeutics Announces $5.9M Award From US Department Of Defense To Further Clinical Development of SPR206,2019-07-16 08:11:00-04:00,SPRO,positive
1174904.0,62 Biggest Movers From Yesterday,2019-06-28 05:20:00-04:00,SPRO,neutral
1174905.0,48 Stocks Moving In Thursday's Mid-Day Session,2019-06-27 12:41:00-04:00,SPRO,neutral
1174906.0,Spero Reports $10M Registered Direct Offering Of Common Stock,2019-06-13 08:01:00-04:00,SPRO,neutral
1174907.0,Spero Therapeutics Highlights SPR994 Data At 29th European Congress Of Clinical Microbiology And Infectious Diseases,2019-04-08 08:33:00-04:00,SPRO,neutral
1174908.0,"Spero Therapeutics Reports Received FDA Fast Track Designation For SPR994 For Treatment Of Complicated Urinary Tract Infections, Acute Pyelonephritis",2019-03-29 08:08:00-04:00,SPRO,neutral
1174909.0,Spero Therapeutics Q4 EPS $(0.60) Up From $(1.59) YoY,2019-03-14 16:37:00-04:00,SPRO,neutral
1174910.0,Spero Therapeutics Reports Received QIDP Designation From FDA For Development OF SPR720,2019-02-26 08:25:00-05:00,SPRO,neutral
1174911.0,Spero Therapeutics Announces the FDA Has Accepted its Investigational New Drug Application for SPR994,2019-02-04 07:05:00-05:00,SPRO,positive
1174912.0,Spero Therapeutics Announces Initiation Of SPR720 Phase 1 Clinical Trial For Non-Tuberculous Mycobacterial Infections,2019-01-29 08:07:00-05:00,SPRO,neutral
1174913.0,Shares of biotech companies with ties to the lung cancer space are trading higher after Bristol-Myers Squibb withdrew its regulatory application for its lung cancer combo drug.,2019-01-24 10:50:00-05:00,SPRO,negative
1174914.0,"The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase",2019-01-08 08:15:00-05:00,SPRO,negative
1174915.0,"Spero Therapeutics Signs License Agreement With Everest Medicines To Develop, Manufacture And Commercialize SPR206 In Asia, With Option For SPR741 Rights, Initiates SPR206 Phase 1 Clinical Trial ; Co. To Receive $2M Upfront And Up To $59.5M In Milestones",2019-01-07 16:03:00-05:00,SPRO,positive
1174916.0,Spero Therapeutics Announces Positive Feedback from FDA Pre-Phase 3 Meeting for Oral SPR994 and Submission of IND for SPR994 in cUTI,2019-01-07 07:46:00-05:00,SPRO,positive
1174917.0,50 Biggest Movers From Yesterday,2018-12-28 05:18:00-05:00,SPRO,neutral
1174918.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,SPRO,negative
1174919.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,SPRO,positive
1174920.0,"The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering",2018-12-06 07:56:00-05:00,SPRO,negative
1174921.0,"Stocks Which Set New 52-Week Lows Fri., Nov. 16, 2018",2018-11-19 10:16:00-05:00,SPRO,negative
1174922.0,UPDATE: Spero Therapeutics Plans To Initiate Phase 1 Trial Of SPR720 In Early 2019,2018-11-05 08:03:00-05:00,SPRO,neutral
1174923.0,Spero Therapeutics Reports Results From SPR720 IND-Enabling Studies: Showed Candidate Achieved 'wide therapeutic margins and activity versus multiple clinically important species of non-tuberculous mycobacteria',2018-11-05 08:02:00-05:00,SPRO,positive
1174924.0,"The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise",2018-10-17 08:15:00-04:00,SPRO,negative
1174925.0,48 Biggest Movers From Yesterday,2018-10-17 05:53:00-04:00,SPRO,neutral
1174926.0,40 Stocks Moving In Tuesday's Mid-Day Session,2018-10-16 12:46:00-04:00,SPRO,neutral
1174927.0,Mid-Day Market Update: Dow Rises Over 350 Points; Hanwha Q CELLS Shares Spike Higher,2018-10-16 12:19:00-04:00,SPRO,positive
1174928.0,10 Biggest Price Target Changes For Tuesday,2018-10-16 09:41:00-04:00,SPRO,neutral
1174929.0,"Benzinga's Top Upgrades, Downgrades For October 16, 2018",2018-10-16 09:14:00-04:00,SPRO,positive
1174930.0,"Bank of America Downgrades Spero Therapeutics to Underperform, Lowers Price Target to $9",2018-10-16 07:34:00-04:00,SPRO,negative
1174931.0,Spero Therapeutics Receives Qualified Infectious Disease Product Designation From FDA FDA For The Development Of SPR206,2018-10-11 08:01:00-04:00,SPRO,neutral
1174932.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-30 10:14:00-04:00,SPRO,neutral
1174933.0,"The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results",2018-09-28 08:10:00-04:00,SPRO,positive
1174934.0,"Spero Announces ""Positive"" Phase 1 SAD/MAD Final Results, Showing A Favorable Safety Profile, Expects To Advance Into a Pivotal Phase 3 Clinical Trial By Year-End",2018-09-27 16:02:00-04:00,SPRO,positive
1174935.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-23 16:10:00-04:00,SPRO,neutral
1174936.0,"Stocks Which Set New 52-Week Low Yesterday, September 17th",2018-09-18 09:27:00-04:00,SPRO,negative
1174937.0,"Stocks Which Set New 52-Week Low Friday, September 14",2018-09-17 09:30:00-04:00,SPRO,negative
1174938.0,Amtech Sees Q4 Sales $26-$28M vs $40M Est.,2018-08-09 16:52:00-04:00,SPRO,neutral
1174939.0,"Spero Therapeutics Q2 EPS $(0.69) vs $(36.21) In Prior Year Period, Sales $463K vs $249K In Prior Year Period",2018-08-09 16:50:00-04:00,SPRO,neutral
1174940.0,"Spero Therapeutics Amended 13D Filing From GlaxoSmithKline Shows Cut Stake From 13.3% As Of Nov. 16, 2017 To 10.7%",2018-07-17 17:07:00-04:00,SPRO,negative
1174941.0,Spero Therapeutics Awarded $15.7M From the Biomedical Advanced Research and Development Authority,2018-07-16 07:00:00-04:00,SPRO,positive
1174942.0,Spero Therapeutics Prices 3.78M Share Public Offering of Commonn Stock @$12.50/Share,2018-07-12 21:14:00-04:00,SPRO,positive
1174943.0,41 Biggest Movers From Yesterday,2018-07-11 04:38:00-04:00,SPRO,neutral
1174944.0,Mid-Afternoon Market Update: OncoCyte Surges Following Positive DetermaVu Study Results; IsoRay Shares Drop,2018-07-10 15:28:00-04:00,SPRO,positive
1174945.0,32 Stocks Moving In Tuesday's Mid-Day Session,2018-07-10 12:20:00-04:00,SPRO,neutral
1174946.0,Mid-Day Market Update: Dow Rises Over 150 Points; Spero Therapeutics Shares Plunge,2018-07-10 12:19:00-04:00,SPRO,positive
1174947.0,Mid-Morning Market Update: Markets Open Higher; PepsiCo Beats Q2 Expectations,2018-07-10 10:15:00-04:00,SPRO,neutral
1174948.0,"7 Stocks To Watch For July 10, 2018",2018-07-10 04:44:00-04:00,SPRO,neutral
1174949.0,Spero Therapeutics Files For 4.5M Share Common Stock Offering,2018-07-09 16:11:00-04:00,SPRO,positive
1174950.0,Spero Says Phase 1 Clinical Data Shows SPR994 To Be Well Tolerated At Single And Multiple Ascending Doses,2018-07-09 07:31:00-04:00,SPRO,positive
1174951.0,48 Biggest Movers From Yesterday,2018-06-20 03:55:00-04:00,SPRO,neutral
1174952.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-06-19 13:44:00-04:00,SPRO,neutral
1174953.0,"UPDATE: Spero Therapeutics Reports SPR206 IND-Enabling Studies Showed Potential For Wide Therapeutic Margins, Broad Antimicrobial Spectrum As Single Agent",2018-05-23 08:08:00-04:00,SPRO,neutral
1174954.0,"Spero Therapeutics Reports Phase 1b Data For SPR741 Study Showed Pharmacokinetic Compatibility, Tolerability When Co-Administered With B-Lactam Antibiotics",2018-05-23 08:08:00-04:00,SPRO,neutral
1174955.0,Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching,2018-05-19 16:10:00-04:00,SPRO,positive
1174956.0,"Benzinga's Top Upgrades, Downgrades For May 11, 2018",2018-05-11 09:38:00-04:00,SPRO,positive
1174957.0,"H.C. Wainwright Initiates Coverage On Spero Therapeutics, Inc. - Common Stock with Buy Rating, Announces $28 Price Target",2018-05-11 07:08:00-04:00,SPRO,neutral
1174958.0,"Spero Therapeutics, Inc. - Common Stock Q1 EPS $(0.74) Up From $(21.60) YoY, Sales $1.153M Up From $140K YoY",2018-05-10 17:06:00-04:00,SPRO,neutral
1174959.0,"Secondary Offering Lockup Expirations Today For: Allena Pharma, Evoqua Water Technologies, Spero Therapeutics, and Funko",2018-05-01 06:55:00-04:00,SPRO,neutral
1174960.0,40 Biggest Movers From Friday,2018-04-16 05:19:00-04:00,SPRO,neutral
1174961.0,"Spero Therapeutics Q4 EPS $(1.59) Misses $(1.35) Est., Grant Sales $993K Beats $330K Est.",2018-04-02 16:18:00-04:00,SPRO,positive
1174962.0,"Nano, Micro-Cap Pharma/Biotech Stocks Up On No Formal News: Syndax Pharma Shares Up 19.2%, Avenue Therapeutics Up 16.1%, Kazia Therapeutics Up 9.9%, Spero Therapeutics Up 6.4%",2018-03-14 13:44:00-04:00,SPRO,neutral
1174963.0,"Benzinga's Top Upgrades, Downgrades For February 9, 2018",2018-02-09 10:17:00-05:00,SPRO,positive
1174964.0,"Cantor Fitzgerald Initiates Coverage On Spero Therapeutics with Overweight Rating, Announces $27.00 Price Target",2018-02-09 06:55:00-05:00,SPRO,negative
1174965.0,"Spero Therapeutics Reports Q3 EPS $(36.02) vs $(23.23) In Same Qtr. Last Year, Sales $597K vs $200K Est.",2017-12-14 16:19:00-05:00,SPRO,neutral
1174966.0,"Benzinga's Top Upgrades, Downgrades For November 27, 2017",2017-11-27 09:05:00-05:00,SPRO,positive
1174967.0,"Bank of America Initiates Coverage On Spero Therapeutics with Neutral Rating, Announces $16.00 Price Target",2017-11-27 08:37:00-05:00,SPRO,neutral
1174968.0,Cowen & Co. Initiates Coverage On Spero Therapeutics with Outperform Rating,2017-11-27 08:09:00-05:00,SPRO,neutral
1174969.0,"Stifel Nicolaus Initiates Coverage On Spero Therapeutics with Buy Rating, Announces $26.00 Price Target",2017-11-27 06:52:00-05:00,SPRO,neutral
1174970.0,Funko Flops As IPO Market Cools Once Again,2017-11-04 14:38:00-04:00,SPRO,negative
1174971.0,Spero Therapeutics Shares Open For Trade At $13.25; IPO Priced At $14/Share,2017-11-02 10:06:00-04:00,SPRO,positive
1174972.0,"IPOs Expected Evoqua Water Technologies (AQUA), Funko (FNKO), Allena Pharmaceuticals (ALNA), Energy Hunter Resources (EHR), and Spero Therapeutics (SPRO)",2017-11-02 09:11:00-04:00,SPRO,positive
1174973.0,"IPOS for Thursday November 2: Evoqua Water Technologies, Funko, Allena Pharmaceuticals, Spero Therapeutics",2017-11-02 05:54:00-04:00,SPRO,neutral
1174974.0,"SmartPros Reports Inline Q3 Loss $0.06, Revs $2.79M, no estimate",2015-11-05 16:17:00-05:00,SPRO,negative
1174975.0,"Benzinga's M&A Chatter for Thursday October 22, 2015",2015-10-22 18:56:00-04:00,SPRO,neutral
1174976.0,Stocks Hitting 52-Week Highs,2015-10-22 10:22:00-04:00,SPRO,neutral
1174977.0,Morning Market Gainers,2015-10-22 09:45:00-04:00,SPRO,neutral
1174978.0,Shares of SmartPros to Resume Trade at 8:30 a.m. EDT,2015-10-22 08:22:00-04:00,SPRO,positive
1174979.0,"Graham Holding's Kaplan Acquires SmartPros For ~$16.9M Cash, 3.57/Share",2015-10-22 07:56:00-04:00,SPRO,neutral
1174980.0,SmartPros Shares Halted-News Pending,2015-10-22 07:55:00-04:00,SPRO,positive
1174981.0,"SmartPros Reports Q2 EPS $0.10 vs. Prior Year Quarter $(0.05), Rev. $3.65M vs. Est. $3.69M",2015-08-06 16:59:00-04:00,SPRO,neutral
1174982.0,"SmartPro Reports Q1 EPS Loss $0.07, Sales $2.71M",2015-05-05 16:11:00-04:00,SPRO,negative
1174983.0,"SmartPros Reports Q4 EPS -$0.35, Sales $13.5M, No Estimates Available",2015-03-05 16:10:00-05:00,SPRO,negative
1174984.0,Stocks Hitting 52-Week Lows,2015-02-18 10:10:00-05:00,SPRO,negative
1174985.0,SmartPros' Skye Multimedia Sells Certain Assets,2015-01-13 16:03:00-05:00,SPRO,positive
1174986.0,"SmartPros Q2 Revenue $4M, EPS -$0.05",2014-08-07 16:14:00-04:00,SPRO,neutral
1174987.0,SmartPros Announces Staffing Reductions And Plans to Close Verticals of Business That Are Not Profitable,2014-06-16 16:20:00-04:00,SPRO,negative
1174988.0,Morning Market Losers ,2013-11-27 09:55:00-05:00,SPRO,negative
1174989.0,SmartPros Ltd. Reports Q3 EPS of $0.00; Revenue of $3.76M,2013-11-07 17:21:00-05:00,SPRO,neutral
1174990.0,Morning Market Losers ,2013-09-18 10:06:00-04:00,SPRO,negative
1174991.0,"SmartPros Ltd. Reports Q2 EPS of $0.01; Revenue of $4.50M, Up 7% YOY",2013-08-06 16:29:00-04:00,SPRO,neutral
1174992.0,Morning Market Movers ,2013-07-08 10:03:00-04:00,SPRO,neutral
1174993.0,SmartPros Raises Qtr. Dividend from $0.0125 to $0.015/Share,2013-03-07 16:18:00-05:00,SPRO,neutral
1174994.0,Morning Market Movers,2013-01-09 09:47:00-05:00,SPRO,neutral
1174995.0,Morning Market Movers,2013-01-08 09:57:00-05:00,SPRO,neutral
1174996.0,SmartPros Reports Q2 EPS $-0.02; Revenues $4.2M,2012-08-07 16:42:00-04:00,SPRO,neutral
1174997.0,SmartPros Acquires Certain Assets of Global Collaboration Partners LLC ,2012-06-14 16:01:00-04:00,SPRO,positive
1174998.0,NASDAQ Stocks Hitting 52-Week Lows,2011-05-31 10:35:00-04:00,SPRO,negative
